Research programme: oncolytic virus cancer therapeutics - DNAtrix

Drug Profile

Research programme: oncolytic virus cancer therapeutics - DNAtrix

Alternative Names: Delta 24 ACT; DNX-2440; DNX-2450; MYX-135

Latest Information Update: 15 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DNAtrix
  • Class Oncolytic viruses
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours
  • Research Haematological malignancies

Most Recent Events

  • 08 Nov 2016 DNAtrix in-licenses myxoma oncolytic virus platform from University of Florida
  • 12 Sep 2016 Early research in Haematological malignancies in USA (Parenteral)
  • 12 Sep 2016 Preclinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top